3,4-Dihydro-2H-1,4-benzoxazine derivatives combining thrombin inhibitory and glycoprotein IIb/IIIa receptor antagonistic activity as a novel class of antithrombotic compounds with dual function

Journal of Medicinal Chemistry

Volumn 51, Issue 18, 2008, Pages 5617-5629

  Ilaš, Janez ^a   Jakopin, Žiga ^a   Borštnar, Tina ^a   Stegnar, Mojca ^b   Kikelj, Danijel ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDRO 2H 1,4 BENZOXAZINE DERIVATIVE; ANTITHROMBOCYTIC AGENT; BENZOXAZINE DERIVATIVE; FIBRINOGEN RECEPTOR ANTAGONIST; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IC 50; MALE; NORMAL HUMAN; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION INHIBITION;

ANTITHROMBINS; BENZOXAZINES; DRUG DESIGN; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MODELS, MOLECULAR; MOLECULAR MIMICRY; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; THROMBIN;

EID: 52449093926     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8003448     Document Type: Article

References (67)

1. (a) Lopez, A. D.; Mathers, C. D.; Ezzati, M.; Jamison, D. T.; Murray, C. J. L. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367, 1747-1757.
2. (b) http://www.who.int/topics/cardiovascular_diseases/en/.
3. (a) Schwienhorst, A. Direct thrombin inhibitors, a survey of recent developments. Cell. Mol. Life Sci. 2006, 63, 2773-2791.
4. (b) Srivastava, S.; Goswami, L. N.; Dikshit, D. K. Progress in the design of low molecular weight thrombin inhibitors. Med. Res. Rev. 2005, 25, 66-92.
5. (c) Steinmetzer, T.; Stürzebecher, J. Progress in the development of synthetic thrombin inhibitors as new orally active anticoagulants. Curr. Med. Chem. 2004, 11, 2297-2321.
6. (a) Kubitza, D.; Haas, S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin. Invest. Drugs 2006, 15, 843-855.
7. (b) Casimiro-Garcia, A.; Dudley, D. A.; Heemstra, R. J.; Filipski, K. J.; Bigge, C. F.; Edmunds, J. J. Progress in the discovery of factor Xa inhibitors. Expert Opin. Ther. Pat. 2006, 16, 119-145.
8. (c) Quan, M. L.; Smallheer, J. M. The race to an orally active factor Xa inhibitor. Recent advances. Curr. Opin. Drug Discovery 2004, 7, 460-469.
9. (a) Lazarus, R. A.; Olivero, A. G.; Eigenbrot, C.; Kirchhofer, D. Inhibitors of tissue factor/factor VIIa for anticoagulant therapy. Curr. Med. Chem. 2004, 11, 2275-2290.
10. (b) Kranjc, A.; Kikelj, D.; Peterlin-Mašič, L. Recent advances in the discovery of tissue factor/factor VIIa inhibitors and dual inhibitors of factor VIIa/factor Xa. Curr. Pharm. Des. 2005, 11, 4207-4227.
11. Andronati, S. A.; Karaseva, T. L.; Krysko, A. A. Peptidomimetics. Antagonists of the fibrinogen receptors: molecular design, structures, properties and therapeutic applications. Curr. Med. Chem. 2004, 11, 1183-1211.
12. (a) Strong, S. H.; Halperin, J. L. Confronting atrial fibrillation in the elderly. Stroke risk stratification and emerging antithrombotic therapies. Geriatrics 2007, 62, 22-27.
13. (b) Ruef, J.; Katus, H. A. New antithrombotic drugs on the horizon. Expert Opin. Invest. Drugs 2003, 12, 781-797.
14. Preželj, A.; Anderuh, P.Š.; Peternel, L.; Urleb, U. Recent advances in serine protease inhibitors as anticoagulant agents. Curr. Pharm. Des. 2007, 13, 287-312.
15. (a) Bode, W. The structure of thrombin: a janus-headed proteinase. Semin. Thromb. Hemostasis 2006, 32 (Suppl. 1), 16-31.
16. (b) Bode, W. The structure of thrombin, a chameleon-like proteinase. J. Thromb. Hemostasis 2005, 3, 2379-2388.
17. Bode, W.; Mayr, I.; Baumann, U.; Huber, R.; Stone, S. R.; Hofsteenge, J. The refined 1.9 Å crystal structure of human α-: interaction with D-Phe-Pro-Arg chloromethyl ketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 1989, 8, 3467-3475.
18. Bajusz, S.; Szell, E.; Bagdy, D.; Barabas, E.; Horvath, G.; Dioszegi, M.; Fittler, Z.; Szabo, G.; Juhasz, A.; Tomori, E.; Szilagyi, G. Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H. J. Med. Chem. 1990, 33, 1729-1735.
19. (a) Hijikata Okunomiya, A.; Okamoti, S. A strategy for a rational approach to designing synthetic selective inhibitors. Semin. Thromb. Hemostasis 1992, 18, 135-149.
20. (b) Rewinkel, J. B. M.; Adang, A. E. P. Strategies and progress towards the ideal orally active thrombin inhibitor. Curr. Pharm. Des. 1999, 5, 1043-1075.
21. Peterlin-Mašič, L.; Kikelj, D. Arginine mimetics. Tetrahedron 2001, 57, 7073-7105.
22. (a) Gustafsson, D.; Bylund, R.; Antonsson, T.; Nilsson, I.; Nystrom, J. E.; Eriksson, U.; Bredberg, U.; Teger-Nilsson, A. C. A new oral anticoagulant: the 50-year challenge. Nat. Rev. Drug Discovery 2004, 3, 649-659.
23. (b) Crowther, M. A.; Weitz, J. I. Ximelagatran: the first oral direct thrombin inhibitor. Expert Opin. Invest. Drugs 2004, 13, 403-413.
24. (c) Evans, H. C.; Perry, C. M.; Faulds, D. Ximelagatran/melagatran. A review of its use in the prevention of venous thromboembolism in orthopaedic surgery. Drugs 2004, 64, 649-678.
25. Hauel, N. H.; Nar, H.; Priepke, H.; Ries, U.; Stassen, J. M.; Wienen, W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J. Med. Chem. 2002, 45, 1757-1766.
26. Zablocki, A. J.; Rico, J. G.; Garland, R. B.; Rogers, T. E.; Williams, K.; Schretzman, L. A.; Rao, S. A.; Bovy, P. R.; Tjoeng, F. S.; Lindmark, R. J.; Toth, M. V.; Zupec, M. E.; Mcmackins, D. E.; Adams, S. P.; Miyano, M.; Markos, C. S.; Milton, M. N.; Paulson, S.; Herin, M.; Jacqmin, P.; Nicholson, N. S.; Panzerknodle, S. G.; Haas, N. F.; Page, J. D.; Szalony, J. A.; Taite, B. B.; Salyers, A. K.; King, L. W.; Campion, J. G.; Feigen, L. P. Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp sequence of fibrinogen (aminobenzamidino)succinyl (ABAS) series of orally active fibrinogen receptor antagonists. J. Med. Chem. 1995, 38, 2378-2394.
27. Curran, M. P.; Keating, G. M. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs 2005, 65, 2009-2035.
28. (a) Cook, J. J.; Bednar, B.; Lynch, J. J.; Gould, R. J.; Egbertson, M. S.; Halczenko, W.; Duggan, M. E.; Hartman, G. D.; Lo, M. W.; Murphy, G. M.; Deckelbaum, L. I.; Sax, F. L.; Barr, E. Tirofiban (Aggrastat). Cardiovasc. Drug Rev. 1999, 17, 199-224.
29. (b) Mukherjee, D.; Roffi, M. Current strategies with high-dose tirofiban. Expert Opin. Drug Metab. Toxicol. 2007, 3, 275-280.
30. (a) Bhatt, D. L.; Topol, E. J. Scientific and therapeutic advances in antiplatelet therapy. Nat. Rev. Drug Discovery 2003, 2, 15-28.
31. (b) McNicol, N.; Israels, S. J. Platelets and anti-platelet therapy. J. Pharmacol. Sci. 2003, 93, 381-396.
32. 3 priming and clustering by orally active and intravenous integrin antagonists. J. Thromb. Hemostasis 2007, 5, 542-550.
33. Xiao, T.; Takagi, J.; Coller, B. S.; Wang, J.-H.; Springer, T. A. Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 2004, 432, 59-67.
34. Štefanič Anderluh, P.; Anderluh, M.; Ilaš, J.; Mravljak, J.; Sollner Dolenc, M.; Stegnar, M.; Kikelj, D. Toward a novel class of antithrombotic compounds with dual function. Discovery of 1,4-benzoxazin-3(4H)-one derivatives possessing thrombin inhibitory and fibrinogen receptor antagonistic activity. J. Med. Chem. 2005, 48, 3110-3113.
35. 18,19
36. (a) Markwardt, F. Coagulation inhibitors from blood-sucking animals. A new line of developing antithrombotic drugs. Pharmazie 1994, 49, 313-316.
37. (b) Nar, H.; Bauer, M.; Schmid, A.; Stassen, J.-M.; Wienen, W.; Priepke, H. W. M.; Kauffmann, I. K.; Ries, U. J.; Hauel, N. H. Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors. Structure 2001, 9, 29-37.
38. (a) Rigbi, M.; Orevi, M.; Eldor, A. Platelet aggregation and coagulation inhibitors in leech saliva and their roles in leech therapy. Semin. Thromb. Hemostasis 1996, 22, 273-278.
39. (b) Waxman, L.; Connolly, T. M. Isolation of an inhibitor selective for collagen-stimulated platelet aggregation from the soft tick Ornithodorus moubata. J. Biol. Chem. 1993, 268, 5445-5449.
40. (c) Nikonov, G. I.; Titova, E. A.; Seleznev, K. G. A stable prostacyclin-like substance produced by the medicinal leech Hirudo medicinalis. Prostaglandins Other Lipid Mediators 1999, 58, 1-7.
41. (a) Bussey, H. I. An overview of anticoagulants, antiplatelet agents, and the combination in patients with mechanical heart valves. J. Heart Valve Dis. 2004, 13, 319-324.
42. (b) Bonow, R. O.; Carabello, B. A.; Chatterjee, K.; de Leon, A. C.; Faxon, D. P.; Freed, M. D.; Gaasch, W. H.; Lytle, B. W.; Nishimura, R. A.; O'Gara, P. T.; O'Rourke, R. A.; Otto, C. M.; Shah, P. M.; Shanewise, J. S.; Smith, S. C.; Jacobs, A. K.; Adams, C. D.; Anderson, J. L.; Antman, E. M.; Faxon, D. P.; Fuster, V.; Halperin, J. L.; Hiratzka, L. F.; Hunt, S. A.; Lytle, B. W.; Nishimura, R.; Page, R. L.; Riegel, B. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. Circulation 2006, 114, E84-E231.
43. (c) Sabatine, M. S.; Tu, T. M.; Jang, I. K. Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase. J. Thromb. Thrombolysis 2000, 10, 189-196.
44. (d) Walenga, J. M.; Jeske, W. P.; Wallis, D. E.; Bakhos, M.; Lewis, B. E.; Leya, F.; Fareed, J. Clinical experience with combined treatment of thrombin inhibitors and GPIIb IIIa inhibitors in patients with HIT. Semin. Thromb. Hemostasis 1999, 25 (Suppl. 1), 77-81.
45. (e) Lincoff, A. M.; Bittl, J. A.; Harrington, R. A.; Feit, F.; Kleiman, N. S.; Jackman, J. D.; Sarembock, I. J.; Cohen, D. J.; Spriggs, D.; Ebrahimi, R.; Keren, G.; Carr, J.; Cohen, E. A.; Betriu, A.; Desmet, W.; Kereiakes, D. J.; Rutsch, W.; Wilcox, R. G.; de Feyter, P. J.; Vahanian, A.; Topol, E. J. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. REPLACE-2 Randomized Trial. JAMA, J. Am. Med. Assoc. 2003, 289, 853-863.
46. (f) Watson, T.; Lip, G. Y. H. Combining antiplatelet drugs and oral anticoagulant therapy in atrial fibrillation: acute coronary syndromes and/or percutaneous coronary intervention/stenting revisited. Stroke 2007, 38, E107-E108.
47. (g) Eikelboom, J. W.; Hirsh, J. Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. J. Thromb. Hemostasis 2007, 5 (Suppl. 1), 255-263.
48. A P3 carboxylic group in some thrombin inhibitors possessing a basic Pi amidine moiety increases oral biovalilability of these compounds and reduces amidine toxicity.
49. (a) Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discovery Today 2004, 9, 641-651.
50. (b) Morphy, J. R.; Rankovic, Z. Designed multiple ligands, an emerging drug discovery paradigm. J. Med. Chem. 2005, 48, 6523-6543.
51. (c) Morphy, R.; Rankovic, Z. The physicochemical challenges of designing multiple ligands. J. Med. Chem. 2006, 49, 4961-4970.
52. (a) Ojima, I.; Chakravarty, S.; Dong, Q. Antithrombotic agents: from RGD to peptide mimetics. Bioorg. Med. Chem. Lett. 1995, 3, 337-360.
53. 3 integrin ligands: pharmacophore refinement and implications for drug design. J. Med. Chem. 2003, 46, 4393-4404.
54. (c) Egbertson, M. S.; Chang, C. T. C.; Duggan, M. E.; Gould, R. J.; Halczenko, W.; Hartman, G. D.; Laswell, W. L.; Lynch, J. J.; Lynch, R. J.; Manno, P. D.; Naylor, A. M.; Prugh, J. D.; Ramjit, D. R.; Sitko, G. R.; Smith, R. S.; Turchi, L. M.; Zhang, G. X. Nonpeptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J. Med. Chem. 1994, 37, 2537-2551.
55. HyperChem, release 5.01 for Windows; Hypercube, Inc.: Gainesville, FL, 1996.
56. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Har, T. W. E.; Belew, R. K.; Olson, A. J. Auomated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
57. Ilaš, J.; Kikelj, D. Ring opening of 2-benzylamino-2H-1,4- benzoxazin-3(4H)-ones and 2-bromo-2H-1,4-benzoxazin-3(4H)- ones. Helv. Chim. Acta 2008, 91, 654-664.
58. - reduction system. Synthetic utility and mode of action. Tetrahedron Lett. 1986, 27, 1205-1208.
59. Roger, R.; Neilson, D. G. The chemistry of imidates. Chem. Rev. 1961, 61, 179-211.
60. Kikelj, D.; Suhadolc, E.; Urleb, U.; Žbontar, U. A convenient synthesis of 3,4-dihydro-2-methyl-3-oxo-2H-1,4-benzoxazine-2-carboxylic acids and 3,4-dihydro-2-methyl-3-oxo-2H-pyrido[3,2-b]-1,4- benzoxazine-2-carboxylic acids. J. Heterocycl. Chem. 1993, 30, 597-602.
61. Mitsunobu, O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1981, 1-28.
62. (a) Abdel-Magid, A. F.; Carson, K. G.; Harris, B. D.; Maryanoff, C. A.; Shah, R. D. Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. Studies on direct and indirect reductive amination procedures. J. Org. Chem. 1996, 61, 3849-3862.
63. (b) Anderluh, M.; Cesar, J.; Štefanic, P.; Kikelj, D.; Janes, D.; Murn, J.; Nadrah, K.; Tominc, M.; Addicks, E.; Giannis, A.; Stegnar, M.; Sollner-Dolenc, M. Design and synthesis of novel platelet fibrinogen receptor antagonists with 2H-1,4-benzoxazine-3(4H)-one scaffold. A systematic study. Eur. J. Med. Chem. 2005, 40, 25-49.
64. Ilaš, J.; Tomašić, T.; Kikelj, D. Novel potent and selective thrombin inhibitors based on a central 1,4-benzoxazin-3(4H)-one scaffold. J. Med. Chem. 2008, 51, 2863-2867.
65. Lee, L.; Kreutter, K. D.; Pan, W.; Crysler, C.; Spurlino, J.; Player, M. R.; Tomczuk, B.; Lu, T. 2-(2-Chloro-6-fluorophenyl)acetamides as potent thrombin inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 6266-6269.
66. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
67. Addicks, E.; Mazitschek, R.; Giannis, A. Synthesis and biological investigation of novel tricyclic benzodiazepinedione-based RGD analogue. ChemBioChem 2002, 3, 1078-1088.